Filtered By:
Drug: Vytorin

This page shows you your search results in order of date. This is page number 13.

Order by Relevance | Date

Total 235 results found since Jan 2013.

High-fat diet leads to same intestinal inflammation as a virus
FINDINGSA new study by scientists at UCLA found that when mice eat a high-fat diet, the cells in their small intestines respond the same way they do to a viral infection, turning up production of certain immune molecules and causing inflammation throughout the body. The scientists also found that feeding the mice tomatoes containing a protein similar to that in HDL, or “good cholesterol,” along with the generic cholesterol drug Ezetimibe, reversed the inflammation.The results could lead to new types of drugs, targeting the intestinal cells, to reduce people ’s risk of heart attacks and strokes, or to treat other cond...
Source: UCLA Newsroom: Health Sciences - June 21, 2017 Category: Universities & Medical Training Source Type: news

The short term effect of atorvastatin plus ezetimibe therapy vs. atorvastatin monotherapy on clinical outcome in the acute coronary syndrome patients by gender.
CONCLUSIONS: The results of our study demonstrated that when added to statin therapy, EZE resulted in improved cardiovascular outcomes and the response to atorvastatin and EZE combination was similar for both men and women. PMID: 28553847 [PubMed - as supplied by publisher]
Source: Polish Heart Journal - May 29, 2017 Category: Cardiology Authors: Japaridze L, Sadunishvili M Tags: Kardiol Pol Source Type: research

Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Original Articles
Conclusions— Addition of ezetimibe to statin therapy in patients with a recent acute coronary syndrome leads to reductions in cardiovascular-related hospitalizations and associated costs, with the greatest cost offsets in high-risk patients. These cost reductions may completely offset the cost of the drug once ezetimibe becomes generic, and may lead to cost savings from the perspective of the healthcare system, if treatment with ezetimibe is targeted to high-risk patients. Clinical Trial Registration— URL: https://www.clinicaltrials.gov. Unique Identifier: NCT00202878
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2017 Category: Cardiology Authors: Pokharel, Y., Chinnakondepalli, K., Vilain, K., Wang, K., Mark, D. B., Davies, G., Blazing, M. A., Giugliano, R. P., Braunwald, E., Cannon, C. P., Cohen, D. J., Magnuson, E. A. Tags: Secondary Prevention, Cost-Effectiveness, Health Services Original Articles Source Type: research

Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.
CONCLUSIONS: Compared with statin monotherapy, ezetimibe with statin therapy was cost-effective for secondary prevention of CHD and stroke and for primary prevention of these conditions in patients whose LDL-C level is ≥ 100 mg/dL and in patients with diabetes, taking into account a 90% cost reduction for ezetimibe. PMID: 28426345 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - April 22, 2017 Category: Health Management Tags: J Med Econ Source Type: research

Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial
ConclusionAlthough intensive lowering with standard pitavastatin plus ezetimibe showed no more cardiovascular benefit than standard pitavastatin monotherapy in ACS patients with dyslipidaemia, statin plus ezetimibe may be more effective than statin monotherapy in patients with higher cholesterol absorption; further confirmation is needed.Trial NoUMIN000002742, registered as an International Standard Randomized Controlled Trial.
Source: European Heart Journal - April 18, 2017 Category: Cardiology Source Type: research

Current status of lipid management in acute coronary syndrome.
Abstract The development of coronary revascularization has dramatically improved early cardiovascular outcomes in patients with acute coronary syndrome (ACS). However, patients who have experienced myocardial infarction (MI) are at high risk of recurrence of cardiovascular events compared with those who are healthy or have stable coronary artery disease. Acute coronary events induce further inflammatory responses and plaque vulnerability in either a coronary culprit or whole vessels. The majority of data have supported the importance of coronary risk management to prevent secondary events. Dyslipidemia is common a...
Source: Journal of Cardiology - March 18, 2017 Category: Cardiology Authors: Fujisue K, Tsujita K Tags: J Cardiol Source Type: research

Rationale and design of REDUCE ‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
Residual cardiovascular risk persists despite statins, yet outcome studies of lipid‐targeted therapies beyond low‐density lipoprotein cholesterol (LDL‐C) have not demonstrated added benefit. Triglyceride elevation is an independent risk factor for cardiovascular events. High‐dose eicosapentaenoic acid (EPA) reduces triglyceride‐rich lipoproteins without raising LDL‐C. Omega‐3s have postulated pleiotropic cardioprotective benefits beyond triglyceride‐lowering. To date, no large, multinational, randomized clinical trial has proved that lowering triglycerides on top of statin therapy improves cardiovascular ou...
Source: Clinical Cardiology - March 14, 2017 Category: Cardiology Authors: Deepak L. Bhatt, Ph. Gabriel Steg, Eliot A. Brinton, Terry A. Jacobson, Michael Miller, Jean ‐Claude Tardif, Steven B. Ketchum, Ralph T. Doyle, Sabina A. Murphy, Paresh N. Soni, Rene A. Braeckman, Rebecca A. Juliano, Christie M. Ballantyne, Tags: TRIAL DESIGNS Source Type: research

Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study.
CONCLUSIONS: Real-world evidence indicates that few high-risk patients initiate therapy with high-intensity statins. More than 50% of patients underwent a rechallenge or switching. Despite high CVD risk profile, approximately 20% of patients permanently discontinued any LLT. Key limitations: Pharmacy claims do not provide information on whether patients who had a pharmacy fill actually took the medication as prescribed. It is unknown whether rechallenge was a simple delay in filling a prescription or an actual rechallenge of their index therapy. Reasons for treatment discontinuations or modifications were unavailable in cl...
Source: Current Medical Research and Opinion - March 10, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

2017 Taiwan lipid guidelines for high risk patients
Publication date: Available online 24 February 2017 Source:Journal of the Formosan Medical Association Author(s): Yi-Heng Li, Kwo-Chang Ueng, Jiann-Shing Jeng, Min-Ji Charng, Tsung-Hsien Lin, Kuo-Liong Chien, Chih-Yuan Wang, Ting-Hsing Chao, Ping-Yen Liu, Cheng-Huang Su, Shih-Chieh Chien, Chia-Wei Liou, Sung-Chun Tang, Chun-Chuan Lee, Tse-Ya Yu, Jaw-Wen Chen, Chau-Chung Wu, Hung-I Yeh In Taiwan, the prevalence of hyperlipidemia increased due to lifestyle and dietary habit changes. Low density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) are all significant predicting factors of ...
Source: Journal of the Formosan Medical Association - February 24, 2017 Category: Journals (General) Source Type: research

2017 Taiwan lipid guidelines for high risk patients.
Abstract In Taiwan, the prevalence of hyperlipidemia increased due to lifestyle and dietary habit changes. Low density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) are all significant predicting factors of coronary artery disease in Taiwan. We recognized that lipid control is especially important in patients with existed atherosclerotic cardiovascular diseases (ASCVD), including coronary artery disease (CAD), ischemic stroke and peripheral arterial disease (PAD). Because the risk of ASCVD is high in patients with diabetes mellitus (DM), chronic kidney disease (CKD) and f...
Source: J Formos Med Assoc - February 23, 2017 Category: Journals (General) Authors: Li YH, Ueng KC, Jeng JS, Charng MJ, Lin TH, Chien KL, Wang CY, Chao TH, Liu PY, Su CH, Chien SC, Liou CW, Tang SC, Lee CC, Yu TY, Chen JW, Wu CC, Yeh HI, Writing Group of 2017 Taiwan Lipid Guidelines for High Risk Patients Tags: J Formos Med Assoc Source Type: research

Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes
Publication date: Available online 26 January 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Eberhard Standl, Oliver Schnell, Darren K McGuire, Antonio Ceriello, Lars Rydén Cardiovascular outcome trials of antihyperglycaemic drugs and non-statin LDL-cholesterol-lowering drugs in patients with type 2 diabetes who have, or who are at high risk of, atherosclerotic cardiovascular disease have provided new evidence that has substantially affected the management of cardiovascular risk in these patients. On the basis of proven cardiovascular and renal benefit, the antihyperglycaemic drugs empagliflozin, lira...
Source: The Lancet Diabetes and Endocrinology - January 25, 2017 Category: Endocrinology Source Type: research

Addition of Ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patient ‐important outcomes
Abstract Ezetimibe is widely used in combination with statins to reduce low‐density lipoprotein. We sought to examine the impact of ezetimibe when added to statins on patient‐important outcomes. Medline, EMBASE, CINAHL, and CENTRAL were searched through July, 2016. Randomized controlled trials (RCTs) of ezetimibe combined with statins versus statins alone that followed patients for at least 6 months and reported on at least one of all‐cause mortality, cardiovascular deaths, non‐fatal myocardial infarctions (MI), and non‐fatal strokes were included. Pairs of reviewers extracted study data and assessed risk of bia...
Source: Journal of Evaluation in Clinical Practice - January 15, 2017 Category: Journals (General) Authors: Yutong Fei, Gordon Henry Guyatt, Paul Elias Alexander, Regina El Dib, Reed A.C. Siemieniuk, Per Olav Vandvik, Mark E. Nunnally, Huda Gomaa, Rebecca L. Morgan, Arnav Agarwal, Ying Zhang, Neera Bhatnagar, Frederick A. Spencer Tags: SYSTEMATIC REVIEW Source Type: research

The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial
Conclusion The clinical benefit of adding ezetimibe to statin appears to be enhanced in patients with prior CABG, supporting the use of intensive lipid lowering therapy in these high-risk patients following ACS.
Source: European Heart Journal - January 12, 2017 Category: Cardiology Authors: Eisen, A., Cannon, C. P., Blazing, M. A., Bohula, E. A., Park, J.-G., Murphy, S. A., White, J. A., Giugliano, R. P., Braunwald, E., on behalf of the IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators Tags: Acute coronary syndromes Source Type: research

Lipids and cerebrovascular disease - New therapeutic options in lowering LDL-cholesterol.
Abstract Stroke is the third most common cause of death worldwide following myocardial infaction and malignancies, furthermore, its functional outcome is the worst of all conditions. Cholesterol, especially LDL-cholesterol plays a key role in the formation of atherosclerotic plaques. It has been verified recently that escalating incidence and mortality of cerebrovascular diseases are proportional to increased levels of LDL-cholesterol. Statin therapy undeniably reduces the risk of stroke, however other methods for decreasing lipid levels have not been proved significantly effective. Preventive effect of high-dose ...
Source: Orvosi Hetilap - November 30, 2016 Category: Journals (General) Authors: Lovadi E, Csécsei P, Lovig C, Karádi Z, Szapáry L Tags: Orv Hetil Source Type: research

ECS guidelines 2016 - dyslipidaemias.
Authors: Sinning D, Landmesser U Abstract Dyslipidaemia is a major cause of atherosclerotic cardiovascular disease and its progression towards clinical complications, such as acute coronary syndromes and stroke. In August 2016 the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) issued new joint guidelines for the management of dyslipidaemias. In these new guidelines, the concept of treating patients to a risk-based low-density lipoprotein (LDL) cholesterol target is reinforced. The task force considers LDL cholesterol as the primary target for dyslipidaemia treatment, whereas h...
Source: Herz - November 16, 2016 Category: Cardiology Tags: Herz Source Type: research